Abstract
Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Algorithms
-
Antibiotic Prophylaxis*
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / adverse effects
-
Antifungal Agents / therapeutic use
-
Child
-
Child, Preschool
-
Female
-
Granulomatous Disease, Chronic / drug therapy*
-
Granulomatous Disease, Chronic / microbiology
-
Humans
-
Male
-
Treatment Outcome
-
Triazoles / administration & dosage*
-
Triazoles / adverse effects
-
Triazoles / therapeutic use
Substances
-
Antifungal Agents
-
Triazoles
-
posaconazole